investor compensation

Rosen Law Firm reminds $PSFE investors of April 7, 2026 deadline in securities lawsuit alleging false statements on ecommerce exposure and credit reserves.

Rosen Law Firm files securities class action against $AQST over alleged misleading statements regarding its Anaphylm drug application between June 2025 and January 2026.

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability and concealed adverse facts.

Rosen Law Firm sued Apollo Global Management for allegedly concealing executive ties to Jeffrey Epstein. Investors have until May 1, 2026 to join.

RegenxBio faces securities class action alleging misleading RGX-111 gene therapy claims; investors have until April 14, 2026 to file.

Rosen Law Firm urges Beyond Meat investors to join class action lawsuit over alleged false statements regarding asset valuations. Lead plaintiff deadline: March 24, 2026.

Investors in $MREO have until April 6, 2026 to join securities class action alleging misleading statements about failed Phase 3 setrusumab trials.

Securities class action filed against NuScale Power over alleged false statements regarding ENTRA1 Energy's nuclear qualifications. Lead plaintiff deadline April 20, 2026.

Rosen Law Firm sues Navan over false IPO disclosures regarding sales, marketing expenses. Lead plaintiff deadline April 24, 2026.

Rosen Law Firm files securities class action against Enphase Energy over alleged misstatements on inventory, financials, and federal credit impacts. Deadline: April 20, 2026.

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability, resulting in earnings miss and weak guidance.

Rosen Law Firm urges Vistagen investors to join securities class action by March 16, 2026, over alleged misstatements regarding fasedienol and clinical trials.

Picard Medical faces securities fraud lawsuit alleging stock manipulation through social media misinformation, insider dumping, and artificial trading. Investors have until April 13, 2026 to join class action.

$SDM investors must act by March 16, 2026 in securities class action alleging market manipulation, false statements, and insider trading violations.

Ultragenyx faces a securities class action alleging misrepresentations about its setrusumab drug's efficacy for osteogenesis imperfecta. Affected investors have until April 6, 2026 to serve as lead plaintiff.

Securities class action filed against $PYPL alleging false statements on 2027 financial targets and Branded Checkout growth. Lead plaintiff deadline April 20, 2026.

Rosen Law Firm files class action against Apollo Global Management ($APO) alleging executives concealed Epstein ties; investors urged to act before deadline.

REGENXBIO faces class action over alleged misleading statements about RGX-111 gene therapy. Investors who bought stock between February 2022 and January 2026 may seek compensation.

Vistagen faces securities fraud lawsuit over fasedienol trial misstatements. Affected investors have until March 16, 2026 deadline to seek lead plaintiff status or secure counsel.

Rosen Law Firm sues Varonis Systems for allegedly misrepresenting ARR projections and SaaS conversion capabilities. Eligible shareholders have until March 9, 2026 to pursue claims.